Phenotypes associated with this allele

• Allele Symbol: Oprd1^tm1Jep
• Allele Name: targeted mutation 1, John E Pintar
• Allele ID: MGI:2387891
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Oprd1^tm1Jep/Oprd1^tm1Jep	involves: 129S/SvEv	MGI:4358697
hm2	Oprd1^tm1Jep/Oprd1^tm1Jep	involves: 129S/SvEv * C57BL/6J	MGI:3639145
cx3	Oprd1^tm1Jep/Oprd1^tm1Jep Oprm1^tm1Jep/Oprm1^tm1Jep Oprm1^tm1Jep/Oprm1^tm1Jep	involves: 129S/SvEv * 129S2/SvPas	MGI:4358720

Genotype
MGI:4358697

hm1

• Allelic Composition: Oprd1^tm1Jep/Oprd1^tm1Jep
• Genetic Background: involves: 129S/SvEv

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

behavior/neurological phenotype ( J:65217 )

N • improgan and DPDPE analgesic responses are normal

Genotype
MGI:3639145

hm2

• Allelic Composition: Oprd1^tm1Jep/Oprd1^tm1Jep
• Genetic Background: involves: 129S/SvEv * C57BL/6J

behavior/neurological

abnormal behavioral response to addictive substance ( J:109209 )

• compared to control, no significant differences in the global withdrawal score under the same chronic treatment of morphine

• develop a level of physical dependence that is at least comparable with that of wild-type mice control

abnormal chemically-elicited antinociception ( J:109209 )

• do not develop analgesic tolerance to morphine

Genotype
MGI:4358720

cx3

• Allelic Composition: Oprd1^tm1Jep/Oprd1^tm1Jep; Oprm1^tm1Jep/Oprm1^tm1Jep; Oprm1^tm1Jep/Oprm1^tm1Jep
• Genetic Background: involves: 129S/SvEv * 129S2/SvPas

behavior/neurological

behavior/neurological phenotype ( J:124042 )

N • mice exhibit normal nociception prior to opioid infusion

impaired behavioral response to morphine ( J:124042 )

• unlike in wild-type mice, mice exhibit decreased tail-withdrawal latencies demonstrating the abolishment of opioid analgesic responses to acute doses of morphine and oxymorphone

• infusion of morphine results in a decrease in tail withdrawal latency relative to baseline after 2 days unlike similarly treated wild-type mice that display an increase on the first two days and a decrease on days 4 through 7

• infusion of oxymorphone results in reduced tail withdrawal latency compared to baseline at 4 days unlike in similarly treated wild-type mice that exhibit an increase in latency within the first 4 days and a decrease on days 8 through 10

• NMDA receptor blockage with MK-801 does not reverse opioid hyperalgesia unlike in similarly treated wild-type mice

impaired behavioral response to anesthetic ( J:124042 )

• unlike in wild-type mice, mice exhibit decreased tail-withdrawal latencies demonstrating the abolishment of opioid analgesic responses to acute doses of morphine and oxymorphone

• infusion of morphine results in a decrease in tail withdrawal latency relative to baseline after 2 days unlike similarly treated wild-type mice that display an increase on the first two days and a decrease on days 4 through 7

• infusion of oxymorphone results in reduced tail withdrawal latency compared to baseline at 4 days unlike in similarly treated wild-type mice that exhibit an increase in latency within the first 4 days and a decrease on days 8 through 10

• NMDA receptor blockage with MK-801 does not reverse opioid hyperalgesia unlike in similarly treated wild-type mice

homeostasis/metabolism

abnormal physiological response to xenobiotic ( J:124042 )

• NMDA receptor blockage with MK-801 does not reverse opioid hyperalgesia unlike in similarly treated wild-type mice